BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
336965
Number of visits today
9
Number of downloads
146921
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Machairas N, Tsilimigras DI, Pawlik TM. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers 2022;14:2018. [DOI: 10.3390/cancers14082018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Machairas N, Papaconstantinou D, Dorovinis P, Tsilimigras DI, Keramida MD, Kykalos S, Schizas D, Pawlik TM. Meta-Analysis of Repeat Hepatectomy versus Radiofrequency Ablation for Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2022;14. [PMID: 36358817 DOI: 10.3390/cancers14215398] [Reference Citation Analysis]
2 Sung PS, Lee IK, Roh PR, Kang MW, Ahn J, Yoon SK. Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1028728] [Reference Citation Analysis]
3 Kouroumalis E, Tsomidis I, Voumvouraki A. Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era? Livers 2022;2:315-335. [DOI: 10.3390/livers2040024] [Reference Citation Analysis]
4 Xue JN, Wang YY, Wang YC, Zhang N, Zhang LH, Lu ZH, Zhao LJ, Zhao HT. Novel cellular therapies for hepatobiliary malignancies. Hepatobiliary Pancreat Dis Int 2022;21:450-4. [PMID: 36100543 DOI: 10.1016/j.hbpd.2022.08.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mastoraki A, Schizas D, Karavolia DM, Smailis A, Machairas N, Vailas M, Michalinos A, Tsapralis D, Anastasiou I, Agrogiannis G. Primary Synovial Sarcoma of the Kidney: Diagnostic Approach and Therapeutic Modalities for a Rare Nosological Entity. JPM 2022;12:1450. [DOI: 10.3390/jpm12091450] [Reference Citation Analysis]
6 Thuru X, Magnez R, El-bouazzati H, Vergoten G, Quesnel B, Bailly C. Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors. Cancers 2022;14:3368. [DOI: 10.3390/cancers14143368] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345